Appel à projets : PHRCK (2015)
Titre : A phase 1 dose-escalation study testing the feasibility and the tolerance of the infusion of a specific third party suicide gene-transduced anti-HLA-DPB10401 CD4+ T cell clone in positive HLA-DPB10401 tumor recipients receiving an allotransplant from a negative HLA-DPB10401 alternative cord blood or haplo-identical donor(s).
Acronyme : AP1DES
Discipline principale : Cancer
Porteur : Thierry GUILLAUME
Établissement : CHU DE NANTES (CHUR), Pays de la Loire
Financement total : 451237 €